共 87 条
- [1] Lembke A(2016)Use of Opioid Agonist Therapy for Medicare Patients in 2013 JAMA Psychiatry. 73 990-992
- [2] Chen JH(2017)Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population Med Care. 55 669-676
- [3] Saloner B(2019)Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs Am J Public Health. 109 434-436
- [4] Daubresse M(2020)Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US JAMA Netw Open. 3 756-764
- [5] Caleb Alexander G(2020)Rural-Nonrural Differences in Telemedicine Use for Mental and Substance Use Disorders Among Medicaid Beneficiaries Psychiatr Serv. 71 1177-1180
- [6] Andrews CM(2018)Telemedicine's Role in Addressing the Opioid Epidemic Mayo Clin Proc. 93 1940-1947
- [7] Abraham AJ(2018)How Is Telemedicine Being Used In Opioid And Other Substance Use Disorder Treatment? Health Aff (Millwood). 37 57-58
- [8] Grogan CM(2020)An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19 Ann Intern Med. 173 108-112
- [9] Westlake MA(2019)Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update J Rural Health. 35 932-934
- [10] Pollack HA(2022)Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage JAMA Netw Open. 5 981-992